Myocardial infarction associated with erenumab: a case report. - Biology of Cardiovascular Diseases Accéder directement au contenu
Article Dans Une Revue Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Année : 2022

Myocardial infarction associated with erenumab: a case report.

Résumé

Monoclonal antibodies acting on the calcitonin gene related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab. A 57-year-old woman with a familial history of coronaropathy, was first treated with erenumab 70 mg for 6 months, then increased to 140 mg. Almost five months after, the patient presented chest pain, increased troponin and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI. Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate exams to measure the burden of coronary atherosclerosis, if necessary.
Fichier principal
Vignette du fichier
Pharmacotherapy - 2022 - Perino - Myocardial infarction associated with erenumab A case report.pdf (2.24 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03696664 , version 1 (16-06-2022)

Identifiants

Citer

Justine Perino, Virginie Corand, Elise Laurent, Hélène Théophile, Ghada Miremont‐salamé, et al.. Myocardial infarction associated with erenumab: a case report.. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, inPress, ⟨10.1002/phar.2706⟩. ⟨hal-03696664⟩

Collections

CNRS U1219 U1034
18 Consultations
101 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More